McKesson revenue
McKesson's revenue was $403.43bn in fiscal 2026, up 12.4% on the year before. Since fiscal 2010 ($108.70bn) it has grown at a compound 8.5% a year. Over the last twelve months it was $410.98bn.
Revenue history
| Fiscal year | 2010Mar 2010 | 2011Mar 2011 | 2012Mar 2012 | 2013Mar 2013 | 2014Mar 2014 | 2015Mar 2015 | 2016Mar 2016 | 2017Mar 2017 | 2018Mar 2018 | 2019Mar 2019 | 2020Mar 2020 | 2021Mar 2021 | 2022Mar 2022 | 2023Mar 2023 | 2024Mar 2024 | 2025Mar 2025 | 2026Mar 2026 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.7 | 112.1 | 122.3 | 122.2 | 137.4 | 179.0 | 190.9 | 198.5 | 208.4 | 214.3 | 231.1 | 238.2 | 264.0 | 276.7 | 309.0 | 359.1 | 403.4 | 411.0 |
| Growth on the year before | — | +3.1% | +9.1% | −0.1% | +12.4% | +30.3% | +6.6% | +4.0% | +4.9% | +2.9% | +7.8% | +3.1% | +10.8% | +4.8% | +11.7% | +16.2% | +12.4% | — |
| Gross profit | 5.7 | 6.0 | 6.4 | 6.9 | 8.4 | 11.4 | 11.4 | 11.3 | 11.2 | 11.8 | 12.0 | 12.1 | 13.1 | 12.4 | 12.8 | 13.3 | 14.6 | 15.0 |
| Gross margin | 5.2% | 5.3% | 5.2% | 5.6% | 6.1% | 6.4% | 6.0% | 5.7% | 5.4% | 5.5% | 5.2% | 5.1% | 5.0% | 4.5% | 4.2% | 3.7% | 3.6% | 3.6% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| North American Pharmaceutical | $337B | 83.7% | ▲ 10.6% |
| Oncology and Multispecialty | $48.4B | 12.0% | ▲ 31.4% |
| Medical Surgical Solutions | $11.5B | 2.9% | ▲ 1.1% |
| Prescription Technology Solutions | $5.8B | 1.4% | ▲ 11.3% |
From McKesson's 10-K filed May 8, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| McKesson | $410.98bn | 8.8% | 13.1% |
| Cencora | $332.77bn | 5.1% | 9.4% |
| Henry Schein | $13.60bn | 6.5% | 2.6% |
| 111, Inc. | $1.75bn | -12.7% | — |
| Cosmos Health Inc. | $73.7m | 33.8% | 14.8% |
| Cellyan Biotechnology Co., Ltd | $13.4m | -33.9% | — |
Compare with peers
- Cencora revenue
- Henry Schein revenue
- 111, Inc. revenue
- Cosmos Health Inc. revenue
- Cellyan Biotechnology Co., Ltd revenue
Head to head: COR vs MCKHSIC vs MCKMCK vs YI
More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies